Powder: -20°C for 3 years | In solvent: -80°C for 1 year
VPC-18005 is a luciferase inhibitor. VPC-18005 inhibits ERG-induced transcription and interacts directly with the ERG-ETS domain thereby disrupting the ERG binding to DNA.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 98.00 | |
5 mg | In stock | $ 247.00 | |
10 mg | In stock | $ 397.00 | |
25 mg | In stock | $ 663.00 | |
50 mg | In stock | $ 945.00 | |
100 mg | In stock | $ 1,280.00 | |
500 mg | In stock | $ 2,570.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 339.00 |
Description | VPC-18005 is a luciferase inhibitor. VPC-18005 inhibits ERG-induced transcription and interacts directly with the ERG-ETS domain thereby disrupting the ERG binding to DNA. |
In vitro | VPC-18005 (1 and 10 µM) produced a 20–30% decrease in the dissemination of cancer cells in zebrafsh[1]. VPC-18005 (5 µM) inhibits pETS-luc reporter activity with IC50s of 3 and 6 μM in PNT1B-ERG and VCaP cells, respectively. VPC-18005 antagonizes the metastatic potential of ERG-expressing prostate cells and suppresses ERG reporter activity without exhibiting overt cytotoxicity. VPC-18005 inhibits migration and invasion of ERG-overexpressing cells in vitro[2]. |
Molecular Weight | 319.38 |
Formula | C15H17N3O3S |
CAS No. | 2242480-48-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 60 mg/mL (187.86 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
VPC-18005 2242480-48-2 Others inhibit VPC18005 ETS VPC 18005 ERG PNT1B cancer prostate Inhibitor inhibitor